Thermo Fisher Scientific CYB561D2 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:1,000

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide corresponding to amino acids 61-110 of Human CYB561D2. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CYB561D2,uniProtId:O14569-1,ncbiNodeId:9606,antigenRange:61-110,antigenLength:222,antigenImageFileName:PA5-75426_CYB561D2_O14569-1_Rabbit.svg,antigenImageFileNamePDP:PA5-75426_CYB561D2_O14569-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 50% glycerol

Contains

0.1% sodium azide

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_2719154

Product Specific Information

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Target Information

CYB561D2 (Cytochrome b561 domain-containing protein 2), also known as putative tumor suppressor protein 101F6, is a 222 amino acid highly hydrophobic protein that contains six membrane spanning domains. Localized to endosomes and endoplasmic reticulum of the perinuclear region, CYB561D2 contains 2 heme-binding sites, through which it reduces ferric ions. CYB561D2 is ubiquitously expressed, with highest levels in lung, liver and kidney. Though expression of CYB561D2 is abundant in normal lung bronchial epithileal cells, CYB561D2 is absent in most lung cancers. The gene encoding CYB561D2 maps to human chromosome 3p21.3, a region that is prone to genetic alterations and is associated with frequent and early allele loss in many human cancers. Exogenous expression of CYB561D2 leads to the induction of caspase-independent apoptotic and autophagic pathways, resulting in the synergistic killing of tumor cells. This suggests an important role for CYB561D2 as a therapeutic intervention in cancer treatment.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.